BiotechTube

HMPL-523(300mg PO QD) + Placebo

Phase 2/3Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Antibody Autoimmune Hemolytic Anemia

Conditions

Warm Antibody Autoimmune Hemolytic Anemia

Trial Timeline

Sep 30, 2022 → Nov 1, 2026

NCT ID
NCT05535933

About HMPL-523(300mg PO QD) + Placebo

HMPL-523(300mg PO QD) + Placebo is a phase 2/3 stage product being developed by HUTCHMED for Warm Antibody Autoimmune Hemolytic Anemia. The current trial status is active. This product is registered under clinical trial identifier NCT05535933. Target conditions include Warm Antibody Autoimmune Hemolytic Anemia.

What happened to similar drugs?

0 of 6 similar drugs in Warm Antibody Autoimmune Hemolytic Anemia were approved

Approved (0) Terminated (1) Active (5)
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
15
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05535933Phase 2/3Active

Competing Products

12 competing products in Warm Antibody Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
APL-2Apellis PharmaceuticalsPhase 2
29
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34